NAVITOCLAX for Neoplasm: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 14 adverse event reports in the FDA FAERS database where NAVITOCLAX was used for Neoplasm.
Most Reported Side Effects for NAVITOCLAX
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Sepsis | 25 | 14.5% | 10 | 22 |
| Pneumonia | 24 | 13.9% | 5 | 23 |
| Thrombocytopenia | 21 | 12.1% | 8 | 12 |
| Febrile neutropenia | 17 | 9.8% | 2 | 16 |
| Pyrexia | 16 | 9.3% | 2 | 15 |
| Fatigue | 14 | 8.1% | 2 | 10 |
| Anaemia | 13 | 7.5% | 1 | 11 |
| Diarrhoea | 13 | 7.5% | 2 | 11 |
| Acute kidney injury | 12 | 6.9% | 5 | 11 |
| Off label use | 11 | 6.4% | 10 | 1 |
| Urinary tract infection | 10 | 5.8% | 1 | 10 |
| Death | 9 | 5.2% | 9 | 3 |
| Multiple organ dysfunction syndrome | 9 | 5.2% | 9 | 6 |
| Dehydration | 8 | 4.6% | 2 | 6 |
| Disease progression | 8 | 4.6% | 6 | 3 |
Other Indications for NAVITOCLAX
Myelofibrosis (58)
Acute lymphocytic leukaemia (30)
Acute lymphocytic leukaemia recurrent (18)
Product used for unknown indication (9)
Acute myeloid leukaemia (5)
Malignant melanoma (5)
T-cell type acute leukaemia (5)
Other Drugs Used for Neoplasm
BEVACIZUMAB (502)
ATEZOLIZUMAB (404)
CYCLOPHOSPHAMIDE (385)
CARBOPLATIN (283)
PACLITAXEL (267)
NIVOLUMAB (219)
OXALIPLATIN (185)
PEMBROLIZUMAB (173)
LENALIDOMIDE (171)
DOXORUBICIN (150)